Mr. Banko’s appointment along with the Company’s recent developments supports the previously announced topline forecast of $1 billion in launch year for Tevogen Bio Oncology and nearly $1 billion for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback